NASDAQ
26.08.26 | 21:59
0,684 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 11.08. | Tela Bio outlines 9- to 12-month sales ramp while withdrawing full-year revenue guidance | 1 | Seeking Alpha | ||
| 10.08. | TELA Bio GAAP EPS of -$0.20 misses by $0.03, revenue of $19.3M misses by $0.71M | 1 | Seeking Alpha | ||
| 04.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 04.08. | TELA Bio names Heather Getz as CEO and Director | 1 | Seeking Alpha | ||
| 04.08. | TELA Bio Names Heather Getz CEO | 2 | RTTNews | ||
| 04.08. | TELA Bio appoints Heather Getz as chief executive officer | 1 | Investing.com | ||
| 04.08. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | TELA Bio, Inc.: TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director | 170 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 20.07. | TELA Bio, Inc.: TELA Bio to Announce Second Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) | ||
| 11.06. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Tela Bio verfehlt Q1-Prognosen: Aktie gibt nach | 2 | Investing.com Deutsch | ||
| 12.05. | TELA Bio Q1 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 12.05. | TELA Bio GAAP EPS of -$0.21 misses by $0.02, revenue of $19.1M beats by $0.1M | 1 | Seeking Alpha | ||
| 12.05. | TELA Bio, Inc.: TELA Bio Reports First Quarter 2026 Financial Results | 218 | GlobeNewswire (Europe) | MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 12.05. | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | TELA Bio, Inc.: TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues | 281 | GlobeNewswire (Europe) | MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 21.04. | TELA Bio, Inc.: TELA Bio to Announce First Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 128,42 | -0,03 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,960 | -4,55 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,372 | +2,16 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| MYRIAD GENETICS | 2,651 | -1,16 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,200 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 | King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 11,080 | 0,00 % | Vir Biotechnology climbs 9% amid post-earnings uptrend | ||
| SUMMIT THERAPEUTICS | 14,230 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| CG ONCOLOGY | 78,42 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,94 | -0,01 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 19,140 | 0,00 % | Erasca, Inc. - 8-K, Current Report | ||
| QIAGEN | 37,340 | +1,72 % | DAX Gewinner am Mittwoch: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| PRAXIS PRECISION MEDICINES | 376,59 | -0,21 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,190 | 0,00 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy | ||
| ARCUTIS BIOTHERAPEUTICS | 25,140 | 0,00 % | Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18K | ||
| DYNE THERAPEUTICS | 26,360 | 0,00 % | Shandong Wit Dyne Health Co., Ltd. Reports Retreat In H1 Income |
Das Unternehmen TELA BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,684 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.